Tonix Pharmaceuticals initiates Phase 2 fibromyalgia trial

Tonix Pharmaceuticals (TNXP) starts a Phase 2b trial for its lead product candidate, the fibromyalgia treatment TNX-102.

Primary endpoint: Change in pain intensity.

Top-line results due in H2 2014. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs